RFA-CK-22-003: Emerging Infections Sentinel Networks (EISN) Research
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Centers for Disease Control and Prevention - ERA notices from 2021.
Centers for Disease Control and Prevention - ERA offered grants of up to $300,000 (at least $200,000) to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make one award worth $1.3 million in total. Applications closed on November 1, 2021.
From the official notice on Grants.gov, last changed September 8, 2021. Checked November 7, 2026.
- Award ceiling$300,000
- Award floor$200,000
- Total funding$1.3 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | August 16, 2021 |
|---|---|
| Deadline | November 1, 2021 |
| Archived by Grants.gov | December 31, 2021 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Hospitals and Medical Centers may also apply
Is this a realistic fit?
- Past Emerging Infections Sentinel Networks awards averaged $5.0 million; this notice allows up to $300,000 per award.
- Most of the program's money (66% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Notice of Funding Opportunity (NOFO) is to provide a funding mechanism for Emerging Infections Sentinel Networks (EISN) research activities, specifically within a network of emergency departments (EDs). The EISN program will assist in operating emergency department provider-based sentinel networks. These networks will contribute to surveillance for emerging infectious diseases (EID), such as those caused by agents of bioterrorism, pathogens of pandemic potential, drug-resistant, foodborne or waterborne microorganisms, and vaccine-preventable or potentially vaccine-preventable diseases (e.g., Bacillus anthracis. new coronaviruses, Clostridium difficile, carbapenem-resistant Enterobacteriaceae, viral hepatitis and respiratory viruses of epidemic or pandemic potential, tuberculosis, sexually transmitted diseases), and help inform operational public health and healthcare decisions during public health emergencies (e.g., assessment of rapid screening and triage protocols during surge of infectious disease cases presenting for clinical care; assessment of clinical characteristics and development of rapid epidemiologic studies during emergencies to improve the understanding of the clinical characteristics, impacts and outcomes of new and emerging diseases), help better understand and address the disproportionate impact of EIDs on underserved and disadvantaged populations, and enhance information exchange.
Who has won Emerging Infections Sentinel Networks grants before
From fiscal 2021 to 2025, Emerging Infections Sentinel Networks (93.860) awarded $25.0 million across 5 grant awards, an average of $5.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| University of California, Los Angeles | California | 1 | $16.5 million |
| Olive View/UCLA Education and Research Institute, Inc. | California | 1 | $5.6 million |
| The International Society of Travel Medicine, Incorporated | Georgia | 1 | $2.8 million |
| Ministry of Health - Tanzania | 1 | $74,910 | |
| The Trustees of Columbia University in the City of New York | New York | 1 | $49,107 |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-CK-22-003 still open?
No. It closed on November 1, 2021.
Who can apply for Emerging Infections Sentinel Networks (EISN) Research?
Centers for Disease Control and Prevention - ERA accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Emerging Infections Sentinel Networks (EISN) Research?
Closed November 1, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $300,000 each. About $1.3 million in total for one award.
Who has won Emerging Infections Sentinel Networks grants before?
The largest recipients over five fiscal years were University of California, Los Angeles, Olive View/UCLA Education and Research Institute, Inc., The International Society of Travel Medicine, Incorporated. The program made 5 awards worth $25.0 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)